Organization (Industry)
GLAUKOS CORPORATION
ClinicalTrials.gov lists GLAUKOS CORPORATION as lead sponsor of 67 trials. It has 47 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers GLAUKOS CORPORATION: 67 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Glaucoma | 52 |
| Glaucoma, Open-Angle | 46 |
| Keratoconus | 11 |
| Cataract | 6 |
| Myopia | 6 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 5 |
| 2024 | 1 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 3 |
| 2018 | 9 |
| 2017 | 3 |
Showing 10 of 21 years.
Prediction, not a registry value: median of 27 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 45 months across 48 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (47)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Gen 2 Travoprost Intracameral Implant | Glaucoma | Phase 3 | 2 |
| Gen 2 Travoprost Intracameral Implant | Glaucoma, Open-Angle | Phase 3 | 2 |
| Timolol eye drops 0.5% | Glaucoma, Open-Angle | Phase 3 | 2 |
| Timolol eye drops 0.5% | Glaucoma | Phase 3 | 2 |
| Sham surgery + active-comparator eye drops | Glaucoma | Phase 3 | 2 |
Showing 5 of 47 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Travoprost | 6 |
| Sham Procedure | 3 |
| Travoprost Intraocular Implant | 1 |
| Topical travoprost | 1 |
| DEXAMETHASONE | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 22% hit target (n=23) | 43% on time (n=21) |
Journals published in (14)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Ophthalmology and therapy | 6 |
| Advances in therapy | 4 |
| Clinical ophthalmology (Auckland, N.Z.) | 4 |
| Drugs | 2 |
| Journal of cataract and refractive surgery | 2 |
Showing 5 of 14 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 113 | 29 | 2025-11-25 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 507,442,000 | -187,691,000 | 150,614,000 |
| 2024 | 383,481,000 | -146,372,000 | 136,425,000 |
| 2023 | 314,711,000 | -134,661,000 | 138,768,000 |
| 2022 | 282,862,000 | -99,195,000 | 123,271,000 |
| 2021 | 294,011,000 | -49,593,000 | 100,999,000 |
| 2020 | 224,959,000 | -120,348,000 | 85,392,000 |
| 2019 | 236,984,000 | 15,424,000 | 68,308,000 |
| 2018 | 181,278,000 | -12,951,000 | 49,676,000 |
| 2017 | 159,254,000 | -92,000 | 38,905,000 |
| 2016 | 114,397,000 | 4,522,000 | 29,223,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (9)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2024-12-16 | Debt financing | not disclosed | Sec extracted |
| 2024-12-05 | Other financing | 53,200,000 | Sec extracted |
| 2024-12-02 | Other financing | not disclosed | Sec extracted |
| 2024-06-28 | Private placement | not disclosed | Sec extracted |
| 2024-06-14 | Private placement | not disclosed | Sec extracted |
Showing 5 of 9 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 7 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Glaukos Corporation | San Clemente, US | FDA | |
| GLAUKOS CORPORATION | Aliso Viejo, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Umeå University | Co sponsors trial with | 2 |
| Jonathon Myers | Co sponsors trial with | 1 |
| Comprehensive EyeCare of Central Ohio | Co sponsors trial with | 1 |
Latest dated events (208)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 208 events.
Biomarker capability evidence (18)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| MCHR2 | Trial sponsor | Named in trial exclusion criteria |
| MCHR2 | Trial sponsor | Named in trial exclusion criteria |
| MCHR2 | Trial sponsor | Named in trial exclusion criteria |
| MCHR2 | Trial sponsor | Named in trial exclusion criteria |
| MCHR2 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 18 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.